$393K
1 filing since 2025 · latest Debt filed
Anavatos Bio is an early-stage Seattle biotechnology company building next-generation protein manufacturing technology for small-batch biologics. Its fit-for-purpose, plug-and-play automated protein manufacturing platform is aimed at early-phase research, pre-clinical, and Phase I clinical material. The company says the platform produces formulated protein from industry-standard materials in eight weeks at 10x less cost than conventional approaches. It was founded in 2025 and is led by Founder and CEO Leah Klein.
What sets it apart
Point-of-need, automated small-batch protein manufacturing that skips centralized CDMO scale, quoted at eight-week turnaround and 10x lower cost using industry-standard materials.
An integrated small-batch manufacturing platform that automates production of custom-designed proteins at the point of need, delivering formulated protein rather than a research-grade prep.
